In the setting of metastatic disease at presentation, systemic therapy with ADT and next-generation androgen receptor (AR) signaling inhibitors (ARSIs), such as enzalutamide, are a first-line therapy to prevent the reactivation of AR signaling [4]. Here, AR is linked to metastatic neoplasm.